Approved drugs with CNS demyelination side effect., page-18

"Pity I don't have time to double up on the scientific studies on the subject"

So sorry that you don't have time to continue wasting our time.

Fact: Clioquinol which was an issue in the early days of Prana discovery has long been out of the picture of Prana's pipeline. There is NO chance of ever going back to clioquinol, so there is no reason to insist upon discussing it. Another fact: your persistent diatribe about demyelination should be on another board of those companies who actually develop drugs to treat diseases such as multiple sclerosis.

Prana's task now and always has been to prove in human clinical trials that PBT2 is not harmful at doses that will be high enough to allow efficacy. The less than stellar evidence of efficacy in Reach2HD Phase II needs further work in another PhaseIIb or will hopefully get to Phase III where efficacy can be tested fully. That is Prana's main concern. For some inexplicable reason they have not been able to achieve that despite their previous assurances.

You should copy your "scientific" ideas to that second-story office addressed to Prana Chief Executive and Board of Directors. They will be thrilled.